Market capitalization | $607.31m |
Enterprise Value | $357.97m |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 154.97 |
P/S ratio (TTM) P/S ratio | 262.90 |
P/B ratio (TTM) P/B ratio | 1.43 |
Sales growth (TTM) Sales growth | 1,734.13% |
Turnover (TTM) Turnover | $2.31m |
As a free StocksGuide basic user, you can view the scores for all 6,953 shares worldwide.
6 Analysts have issued a Lexicon Pharmaceuticals, Inc. forecast:
6 Analysts have issued a Lexicon Pharmaceuticals, Inc. forecast:
Mar '24 | |
Current assets | 365 365 |
Fixed assets | 53 53 |
Total assets | 417 417 |
Mar '24 | |
Equity | 289 289 |
Debt capital | 128 128 |
Total capital | 417 417 |
Figures in millions USD.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include XERMELO, Zynquista, and LX9211. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.
Head office | United States |
CEO | Lonnel Coats |
Employees | 285 |
Founded | 1995 |
Website | www.lexpharma.com |
StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.